
Victoza
Liraglutide
- SKU
- 50090-2853
- Mfr
- A-S Medication Solutions
3 ml in 1 syringe, plastic, 3 syringe, plastic in 1 carton
$1,066.99
Price for one pack
Prescription required. Upload your prescription at checkout or email it to us after ordering. We ship once a pharmacist has checked it. How it works
3 )] . Limitations of Use : VICTOZA should not be used in patients with type 1 diabetes mellitus. VICTOZA contains liraglutide and should not be coadministered with other liraglutide-containing products.
- Strength
- Liraglutide 6 mg/mL
- Unit of measure
- Per mL
- Dosage form
- Injection
- Route
- Subcutaneous
Pharmacologic class
- GLP-1 Receptor AgonistEstablished class
- Glucagon-Like Peptide 1Chemical structure
- Glucagon-like Peptide-1 (GLP-1) AgonistsMechanism
- Brand name
- Victoza
- Generic name
- Liraglutide
- Manufacturer
- A-S Medication Solutions
- Product NDC (SKU)
- 50090-2853
- Active ingredients
- Liraglutide 6 mg/mL
- Unit of measure
- Per mL
- Dosage form
- Injection
- Route
- Subcutaneous
- DEA schedule
- Not controlled
- Product type
- HUMAN PRESCRIPTION DRUG
- Marketing category
- NDA
- Application number
- NDA022341
- Marketed since
- January 25, 2010
- Label revised
- February 6, 2023
| Package NDC | Description |
|---|---|
| 50090-2853-0 | 3 SYRINGE, PLASTIC in 1 CARTON (50090-2853-0) / 3 mL in 1 SYRINGE, PLASTIC |
Reading this NDC
50090-2853-0
- 01Labeler code
- A-S Medication Solutions
- 02Product code
- Victoza, injection
- 03Package code
- 3 syringe, plastic in 1 carton (50090-2853-0) / 3 ml in 1 syringe, plastic
Liraglutide is an acylated human Glucagon-Like Peptide-1 (GLP-1) receptor agonist with 97% amino acid sequence homology to endogenous human GLP-1(7-37). GLP-1(7-37) represents <20% of total circulating endogenous GLP-1. Like GLP-1(7-37), liraglutide activates the GLP-1 receptor, a membrane-bound cell-surface receptor coupled to adenylyl cyclase by the stimulatory G-protein, Gs, in pancreatic beta cells.
Liraglutide increases intracellular cyclic AMP (cAMP) leading to insulin release in the presence of elevated glucose concentrations. This insulin secretion subsides as blood glucose concentrations decrease and approach euglycemia. Liraglutide also decreases glucagon secretion in a glucose-dependent manner. The mechanism of blood glucose lowering also involves a delay in gastric emptying.
GLP-1(7-37) has a half-life of 1.5-2 minutes due to degradation by the ubiquitous endogenous enzymes, dipeptidyl peptidase IV (DPP-IV) and neutral endopeptidases (NEP). Unlike native GLP-1, liraglutide is stable against metabolic degradation by both peptidases and has a plasma half-life of 13 hours after subcutaneous administration. The pharmacokinetic profile of liraglutide, which makes it suitable for once daily administration, is a result of self-association that delays absorption, plasma protein binding and stability against metabolic degradation by DPP-IV and NEP.
Warning: Risk of thyroid c-cell tumors
- Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether VICTOZA causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions
and Nonclinical Toxicology].
- VICTOZA is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of VICTOZA and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with VICTOZA [see Contraindications
and Warnings and Precautions]. WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning.
- Liraglutide causes thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether VICTOZA causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined.
- VICTOZA is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and the symptoms of thyroid tumors.
VICTOZA is indicated:
- as an adjunct to diet and exercise to improve glycemic control in patients 10 years and older with type 2 diabetes mellitus,
- to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease. Limitations of Use: VICTOZA should not be used in patients with type 1 diabetes mellitus. VICTOZA contains liraglutide and should not be coadministered with other liraglutide-containing products. VICTOZA is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated:
- as an adjunct to diet and exercise to improve glycemic control in patients 10 years and older with type 2 diabetes mellitus
.
- to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. Limitations of Use:
- Not for treatment of type 1 diabetes mellitus.
- Should not be coadministered with other liraglutide-containing products.
Read before you order

Weight management · 3 min read
How GLP-1 weight-loss medicines work
Semaglutide, tirzepatide and liraglutide explained: how they reduce appetite, how quickly they work and what to expect in the first months.

Weight management · 2 min read
Managing nausea and other GLP-1 side effects
Practical ways to cope with nausea, constipation and reflux on semaglutide or tirzepatide, and the warning signs that need a doctor.

Weight management · 2 min read
Orlistat, phentermine and Contrave: the older weight-loss medicines
How orlistat, phentermine and naltrexone-bupropion work, who they suit and the side effects to know about before starting.
More in Weight Management
View all
Brand · Capsule
Alli
Orlistat 60 mg/1
- SKU
- 0135-0461
- Mfr
- Haleon US Holdings LLC
From $47.99Min. 7 packs

Brand · Capsule
Alli
Orlistat 60 mg/1
- SKU
- 71610-805
- Mfr
- Aphena Pharma Solutions - Tennessee, LLC
From $1,329.43

Brand · Tablet
Contrave Extended-Release
Naltrexone Hydrochloride 8 mg/1, Bupropion Hydrochloride 90 mg/1
- SKU
- 51267-890
- Mfr
- Nalpropion Pharmaceuticals LLC
From $199.00Min. 2 packs

Brand · Injection
Mounjaro
Tirzepatide 4.17 mg/mL
- SKU
- 0002-4052
- Mfr
- Eli Lilly and Company
From $1,454.99